← Back to Search

Metabolic Pathway Analysis for Pancreatic Cancer

N/A

Recruiting

Led By Howard S Hochster, MD

Research Sponsored by Rutgers, The State University of New Jersey

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Willing to undergo mandatory intraoperative small excisional and core biopsies (4-6 passes) of tumor and normal tissue for research purposes at the time of proposed pancreatectomy

Pancreatic adenocarcinoma patients previously diagnosed by biopsy, who are candidates for intended curative resection either with or without neoadjuvant chemotherapy

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 2 years

Awards & highlights

Study Summary

This trial looks at what nutrients pancreatic cancer cells need to survive and how they get them. Researchers will give patients U-13C-glucose during surgery and then study the cancer cells in the lab. This may help researchers understand how cancer cells get nutrients and why they are different from normal cells.

Who is the study for?

This trial is for adults with pancreatic adenocarcinoma, eligible for surgery. It includes both untreated patients and those who've had chemotherapy but no other cancer treatments like radiation or immunotherapy. Participants must understand the study's experimental nature and consent to biopsies during surgery.Check my eligibility

What is being tested?

The trial studies how pancreatic cancer cells manage nutrients by using a special form of glucose given during surgery. Researchers will compare the metabolism of cancerous and normal cells from biopsies to better understand the disease.See study design

What are the potential side effects?

Since this trial involves standard surgical procedures and biopsies, potential side effects include typical surgical risks such as infection, bleeding, pain at the incision site, and possible complications from anesthesia.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I agree to have extra biopsies taken during my surgery for research.

Select...

I have pancreatic cancer and am a candidate for surgery aimed at curing it, with or without prior chemotherapy.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

To measure glycolysis metabolism dependencies via liquid chromatography-mass spectrometry (LC-MS)

Secondary outcome measures

To measure lipid metabolic dependencies via liquid chromatography-mass spectrometry (LC-MS)

Other outcome measures

To measure amino acid metabolism dependencies via liquid chromatography-mass spectrometry (LC-MS)

Trial Design

1Treatment groups

Experimental Treatment

Group I: Basic science (uniformly-labeled [13C]glucose)Experimental Treatment3 Interventions

Patients receive uniformly-labeled [13C]glucose IV over 10 minutes and then over up to 120 minutes until time of biopsy. Patients then undergo surgery and biopsy per standard of care.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Therapeutic Conventional Surgery

2005

Completed Phase 3

~9850

Biopsy

2014

Completed Phase 4

~1090

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Rutgers, The State University of New JerseyLead Sponsor

429 Previous Clinical Trials

64,216 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,662 Previous Clinical Trials

40,926,057 Total Patients Enrolled

Howard S Hochster, MDPrincipal InvestigatorRutgers Cancer Institute of New Jersey

1 Previous Clinical Trials

42 Total Patients Enrolled

Media Library

Therapeutic Conventional Surgery Clinical Trial Eligibility Overview. Trial Name: NCT05296421 — N/A

Pancreatic Cancer Research Study Groups: Basic science (uniformly-labeled [13C]glucose)

Pancreatic Cancer Clinical Trial 2023: Therapeutic Conventional Surgery Highlights & Side Effects. Trial Name: NCT05296421 — N/A

Therapeutic Conventional Surgery 2023 Treatment Timeline for Medical Study. Trial Name: NCT05296421 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are enrolled in this research program?

"Correct. Clinicaltrials.gov indicates that this research endeavour, which was established on March 14th 2022, is still actively recruiting candidates. 16 volunteers need to be found from 2 different locations."

Answered by AI

Are there still opportunities for patient enrollment in this clinical trial?

"Affirmative. As per the information hosted on clinicaltrials.gov, this trial has been ongoing since March 14th 2022 and is still actively recruiting participants from two medical centres with a target of 16 patients in total."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer

Howard S. Hochster, MD 2022. "Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05296421.